Case report: Refractory intestinal Behçet’s syndrome successfully treated with tofacitinib: A report of four cases

Na Zhao, Yanchun Tang, Shaokun Wang, Liping Cui, Xuehui Sun, Zhihua Wang, Ying LiuFrontiers in Immunology 2022 · DOI

TL;DR

This case series demonstrates that tofacitinib, an oral Janus kinase (JAK) inhibitor, can successfully induce complete endoscopic healing in patients with severe, refractory intestinal Behçet’s syndrome. For patients who fail standard treatments like corticosteroids and anti-TNF biologics, JAK inhibition offers a promising new therapeutic pathway to prevent life-threatening complications like intestinal perforation.

What Problem Does This Paper Address?

Behçet’s syndrome (BS) is a chronic, multisystem inflammatory disorder characterized by vasculitis. While it commonly presents with oral and genital ulcers, the "intestinal" subtype is particularly dangerous. It causes deep, "volcano-shaped" ulcers in the digestive tract that can lead to gastrointestinal bleeding, fistulas, and bowel perforation.

The current "gold standard" for treatment involves glucocorticoids and immunosuppressants, often escalating to monoclonal anti-TNF antibodies (biologics) for tough cases. However, many patients are "refractory"—meaning they don't respond to these drugs—or they cannot use biologics due to severe allergic reactions, the inconvenience of frequent injections, or logistical hurdles (such as those seen during the COVID-19 pandemic). There is currently no recognized radical cure, and failing to achieve "endoscopic remission" (visible healing of the gut lining) significantly lowers a patient's quality of life and survival.

Methods

The authors present a retrospective case report of four patients (one male, three females, ages 20–67) treated at Yantai Yuhuangding Hospital in China. All four suffered from severe intestinal BS that had failed multiple lines of traditional therapy, including corticosteroids, thalidomide, and various immunosuppressants (like methotrexate or cyclophosphamide). One patient also had to discontinue the biologic infliximab due to an allergic rash.

The intervention involved administering tofacitinib (TOF), typically at a dose of 5 mg twice daily, often in combination with salazosulfapyridine (SASP). The researchers monitored progress using:

  • DAIBD: The Disease Activity Index for Intestinal Behçet’s Disease.
  • Inflammatory Markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
  • Enteroscopy: Direct visual inspection of the intestinal mucosa to confirm ulcer healing.

Datasets

As a case series, the "dataset" consists of the detailed clinical histories, laboratory longitudinal data, and endoscopic imagery of the four specific patients. The authors also referenced existing literature regarding the JAK-STAT signaling pathway's role in BS pathogenesis to justify the use of TOF.

Key Insights and Ideas

  • The Th1/Th17 Connection: The paper highlights that the pathogenesis of BS is driven by T-cell dysfunction, specifically the over-activation of Helper T cells (Th1 and Th17). Tofacitinib works by inhibiting JAK1 and JAK3, which effectively blocks the signaling of cytokines (like IL-6 and IFN-$\gamma$) that drive this destructive T-cell differentiation.
  • Endoscopic Healing vs. Symptom Relief: The authors emphasize that simply feeling better isn't enough. The "ultimate treatment goal" is endoscopic remission. In all four cases, TOF didn't just reduce pain; it physically closed deep, chronic ulcers that had persisted for months or years under other treatments.
  • Steroid-Sparing Effect: One of the most significant insights is TOF's ability to act as a "steroid-sparing" agent. Chronic steroid use has devastating side effects; in three of the four cases, TOF allowed patients to discontinue prednisone entirely.

Key Results

The results across all four cases were remarkably consistent:

  • Clinical Success: All four patients achieved "success" as defined by the resolution of symptoms and normalization of lab markers.
  • Rapid Response: Inflammatory markers (ESR and CRP) and DAIBD scores dropped sharply within the first 3–6 months of TOF treatment (see Figure 2 in the paper).
  • Visual Confirmation: Enteroscopy performed after several months of TOF treatment showed that previously large, deep ileocecal ulcers had completely healed.
  • Long-term Stability: Follow-up periods ranged from 10 to 33 months, with all patients remaining in remission. For example, Case 1 (a 67-year-old male) remained in success for 33 months, eventually reducing his TOF dose to just 5 mg once daily.

Limitations and Future Work

The primary limitation is the small sample size. While the results are compelling, a four-patient case series cannot establish broad clinical guidelines.

The authors also note a critical nuance: previous studies showed TOF might be less effective in patients who have already developed severe structural complications like fistulas or perforations. Therefore, they suggest that early addition of TOF might be the best strategy for refractory patients before irreversible damage occurs.

Future work will require larger, multi-center randomized controlled trials (RCTs) to confirm these findings, establish long-term safety profiles, and determine the optimal timing for introducing JAK inhibitors in the treatment algorithm for Behçet’s syndrome.

Summary updated

Abstract

Behçet's syndrome (BS) is a chronic form of relapsing multisystem vasculitis, characterized by recurrent oral and genital ulcers. Intestinal BS is a special type of BS. Volcano-shaped ulcers in the ileocecum are a typical finding of intestinal BS, and punched-out ulcers can be observed in the intestine or esophagus. At present, there is no recognized radical treatment for intestinal BS. Glucocorticoids and immunosuppressants are currently the main drugs used to improve the condition. Although it has been reported that monoclonal anti-TNF antibodies may be effective for some refractory intestinal BS, further randomized, prospective trials are necessary to confirm these findings. Some patients are restricted from using biological agents because of serious allergic reactions of drugs, inconvenient drug injections or the impact of the novel coronavirus epidemic. If endoscopic remission (endoscopic healing) is not achieved for a prolonged period of time, serious complications, such as perforation, fistula formation, and gastrointestinal bleeding can be induced. Therefore, it is necessary to develop new treatment methods for controlling disease progression. We reviewed the relevant literature, combined with the analysis of the correlation between the pathogenesis of BS and the mechanism of Janus kinase (JAK) inhibition, and considered that tofacitinib (TOF) may be effective for managing refractory intestinal BS. We report for the first time that four patients with severe refractory intestinal BS were successfully treated with TOF. We hope to provide valuable information on JAK inhibitors as potential therapeutic targets for the treatment of severe refractory intestinal BS.
BibTeX
@inproceedings{zhao2022case,
  author = {Na Zhao and Yanchun Tang and Shaokun Wang and Liping Cui and Xuehui Sun and Zhihua Wang and Ying Liu},
  title = {{Case report: Refractory intestinal Behçet’s syndrome successfully treated with tofacitinib: A report of four cases}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.981502},
}
Figure